Medieval wellness is back—and it's all over your FYP
After examining hundreds of medieval manuscripts and compiling their findings into a catalog, a new international research project sheds fresh light on early medieval medical practices—many of which wouldn't be out of place on TikTok 's For You Page.
As the MAHA (Make America Healthy Again) sect and wellness girlies gain traction both online and in the Oval Office, natural remedies are back in vogue. From beef tallow as skincare to castor oil in the belly button, these hacks could just as easily have been scribbled in the margins of a 5th-century manuscript as featured in an influencer's get-ready-with-me video in 2025.
'A lot of things that you see in these manuscripts are actually being promoted online currently as alternative medicine, but they have been around for thousands of years,' wrote Meg Leja, an associate professor of history at Binghamton University. Whether that's a good or bad thing depends on who you ask.
One medieval hack involves rubbing a mixture of crushed peach pit and rose oil on the forehead as a cure for headaches. Science now backs this up—a study from 2017 suggests rose oil may help relieve migraine pain.
Another 9th-century hair hack recommends covering the scalp with herbal-infused salt and vinegar to disinfect it, followed by a salve of oils mixed with the 'ashes of a burnt green lizard' to enhance shine. Perhaps not one to try at home.
Other topical ointments and detox cleanses made from dried herbs and distilled alcohols share similarities with recent TikTok trends, like drinking 'tadpole water' for debloating or eating dirt to reduce wrinkles.
Many of these medieval health and beauty hacks were found scribbled in the margins of books unrelated to medicine, suggesting a preoccupation with wellness that feels distinctly modern.
'People were engaging with medicine on a much broader scale than had previously been thought,' Leja told Science Daily. 'They were concerned about cures, they wanted to observe the natural world and jot down bits of information wherever they could in this period known as the 'Dark Ages.''
Sounds like they would've loved TikTok.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
MASSIVE BIO Delivers on CMS Interoperability Vision with Live Patient Connect App and AI Trial Matching Assistant
BOCA RATON, Fla., July 31, 2025--(BUSINESS WIRE)--In direct support of the White House and CMS's bold initiative to "Make Health Tech Great Again," Massive Bio, leader in AI-enabled oncology trial matching, announced its full alignment with the CMS Health Tech Ecosystem and reaffirmed its mission to modernize clinical trial access through secure, AI-powered patient-facing technology. With its Patient Connect app and intelligent assistant DrArturoAI already live and serving patients, Massive Bio stands as one of the first organizations actively delivering on CMS's interoperability framework at scale. "We're not waiting for transformation, we've already launched it," said Selin Kurnaz, PhD, CEO and Co-Founder of Massive Bio. "Patient Connect represents a new era of patient empowerment: secure identity, real-time data access, AI-guided decision-making. We've operationalized CMS's vision, and we're proud to serve the public with technology that puts them in control of their care journey." Patient Connect enables individuals to upload and verify medical records, match to clinical trials using AI, communicate with coordinators, and share data securely with providers. Already in use by thousands of cancer patients globally, the platform integrates key CMS features such as "kill the clipboard" (FHIR-based digital check-in), IAL2/AAL2 identity verification, and Medicare connectivity. "This is infrastructure for health equity," said Cagatay Culcuoglu, CTO and Co-Founder. "We've engineered Patient Connect to comply with FHIR standards, Smart Health Cards, and seamless credentialing, removing fragmentation and putting data back into the hands of those it belongs to: the patient." The company's virtual assistant, DrArturoAI, complements the app by offering conversational, context-aware AI support. Patients can receive educational guidance, symptom triage, care navigation, and trial opportunities; all transparently flagged when AI-generated and seamlessly integrated with provider care pathways. "With DrArturoAI, we've built something that feels human, helpful, and honest," said Dr. Arturo Loaiza-Bonilla MD, Chief Medical Officer and Co-Founder. "It's the bridge between fragmented data and actionable care. Our prescreening hubs and AI-powered analytics create a mission-control capability that works 24/7 to identify and match patients in full patient centricity. This is responsible AI in service of patients, and a model for how CMS-aligned health tech can serve every American." What Massive Bio Has Already Delivered CMS Pillar Massive Bio Implementation Kill the Clipboard Digital FHIR check-in, QR/Smart Health Cards, visit summaries AI-Powered Assistant DrArturoAI & AskFionaAI: Safe, transparent, triage & support CMS Identity Compliance IAL2/AAL2 credentials, Medicare notifications, HIPAA compliant Chronic Condition Support Trial eligibility tied to clinical record insights for cancer, obesity, prediabetes A National Commitment to Patient-Centered Innovation Massive Bio is actively collaborating with CMS and fellow early adopters to help operationalize the interoperability framework, participate in app store pilots for and expand patient access through aligned health systems and pharmacy networks. "We salute CMS for spearheading a future-ready ecosystem that prioritizes transparency, equity, and access," said Kurnaz. "This isn't just compliance, it's our calling." About Massive Bio Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit Explore Patient Connect → Meet DrArturoAI → View source version on Contacts Media Contact: Massive BioMert Turkkan,Marketing Directormturkkan@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
23 minutes ago
- New York Times
New Implant Offers Hope for Easing Rheumatoid Arthritis
The Food and Drug Administration on Wednesday approved a medical device that offers new hope to patients incapacitated by rheumatoid arthritis, a chronic condition that afflicts 1.5 million Americans and is often resistant to treatment. The condition is usually managed with medications. The device represents a radical departure from standard care, tapping the power of the brain and nervous system to tamp down the uncontrolled inflammation that leads to the debilitating autoimmune disease. The SetPoint System is an inch-long device that is surgically implanted into the neck, where it sits in a pod wrapped around the vagus nerve, the largest nerve in the body. The device electrically stimulates the nerve, a sort of information freeway through the body, for one minute each day. The stimulation can turn off crippling inflammation and 'reset' the immune system, research has shown. Most drugs used to treat rheumatoid arthritis suppress the immune system, leaving patients vulnerable to serious infections. On a recent episode of the American College of Rheumatology podcast, the SetPoint implant was described as representing a 'true paradigm shift' in treatment of the disease, which until now has relied almost entirely on an evolving set of pharmaceutical interventions, from gold salts to powerful agents called biologics. The designated the implant as a breakthrough last year in order to expedite its development and approval. It represents an early test of the promise of so-called bioelectronic medicine to modulate inflammation, which plays a key role in diseases including diabetes, heart disease and cancer. Want all of The Times? Subscribe.
Forbes
23 minutes ago
- Forbes
'The M Factor' Makers Create A Perimenopause Film: 'Before The Pause'
The creators of The M Factor are working on a follow up documentary about perimenopause The M Factor Menopause got a dose of long-overdue attention with the hit documentary The M Factor: Shredding The Silence On Menopause , which revolutionized how women (and doctors) think and talk about menopause. It was screened in 700 cities around the world, including at the World Economic Forum in Davos. But, as so many millennial and Gen X women know, the story doesn't start with menopause, which usually happens around 51 years-old. Hormonal changes can start as young as 35, which is a transition called perimenopause that's even less well-understood than menopause. The team who made The M Factor are on the case—they're planning a March 2026 release of Before the Pause , a documentary that will focus specifically on perimenopause. Jacoba Atlas will be the director, and Joanne LaMarca Mathison, a former executive producer of the Today show as well as The M Factor, will be a co-producer. 'This film is going to focus on what women can do beforehand to start prepping for the next 30 years of their lives,' says Tamsen Fadal, an executive producer on both documentaries, a former news anchor, and author of the New York Times bestselling book How To Menopause . Following screenings of The M Factor , women lined up to talk to the filmmakers, wanting to know 'When's the next film?' So they put their heads together and realized the logical next step would be to start the story earlier in the timeline with perimenopause. 'We're going to start this conversation earlier—like at 35,' says Denise Pines, another executive producer of The M Factor and Before the Pause, and president of the Osteopathic Medical Board of California. 'Symptoms actually start to emerge then. Women know something's going on, their body is starting to change, but they're not thinking these are early perimenopause symptoms.' That's why Before the Pause will focus on women in their 30s and 40s, who, when they report hormonal symptoms, are often dismissed by doctors. 'Women are still coming to us confused and scared, and honestly there's no area of your life that's untouched by this season of life, whether it's perimenopause or menopause,' Fadal says. Doctors Aren't Ready And Women Are Paying The Price Despite her proximity to the medical profession, Pines says she was unprepared for her own perimenopausal symptoms. 'Not once did a doctor say—not my OB/GYN, not my general practitioner—'You know, Denise, you're 48 and you might start to see some of these things show up ... there are solutions and we can talk about some options,'' she said. 'Never, not once, never ever. Countless women have similar stories, including Fadal, who said she thought she was too young for menopause symptoms in her late 40s. 'I was 49 when I hit menopause,' she says. That disconnect between life experience and medical practice became the core of The M Factor , and continues to drive the new film. The documentary makers want women to understand that the health system isn't set up to usher women through this transition. General practitioners have little time to spend with each patient, so they refer them to an OB/GYN. But, as The M Factor made clear, even OB/GYNs have surprisingly little training in menopause or perimenopause care. 'I'm tired of seeing smart, capable women feel blindsided by a stage of life that nobody warned them about,' Fadal says. Data Gaps, Misinformation, And The Legacy Of The Women's Health Initiative Study When the filmmakers searched for data on how many women use hormone therapy, they were shocked by what they found. Data showed that just 4.7% of women were taking hormone replacement therapy, also known as HRT, to treat their menopausal symptoms, which includes hot flashes, brain fog, depression, and a long list of many more. That number had plummeted from almost 27% in 1999. But what was really shocking was data released just days before delivering final cut of the film. A new report put the number at just 1.8%. 'In some age groups it was even lower than that,' Pines says. The steep decline is a direct result of lingering fear sparked by a 2002 blockbuster study released by the Women's Health Initiative. It linked hormone therapy to serious health risks, including breast cancer. But the study was flawed in many ways—for example, the researchers recruited patients over 60 (about a decade older than the typical patient starting HRT). A quarter of a century later—despite research showing that HRT is not only safe for most patients but also protective against other complications including cardiovascular disease and osteoporosis—a lingering fear of HRT remains among both patients and doctors. 'You still have doctors who will not prescribe HRT,' Pines said. 'They will tell you they don't believe in it.' The M Factor began to mitigate that fear, and the filmmakers hope After the Pause will continue the trend by helping women begin a conversation about HRT with their doctors even earlier. Measuring The Power of Media Despite systemic resistance, The M Factor proved that education can move the needle—and a new report shows just how widespread and impactful the film was. 'We were told there was no audience for this kind of topic,' Fadal says. 'That it was 'niche.' A niche topic that affects half the population of the world." Following screenings in all 50 states and 50 countries around the world world, the filmmakers conducted pre- and post-screening surveys and found that a significant number of women who were not already taking HRT did a 180. 'It was crazy—around a 400% increase (in interest in trying HRT) from watching a 60-minute film,' Pines says. They're hoping for a similar impact with the new documentary. 'If we start talking at 35 instead of 50, we change everything,' she says.
